Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 3/2017

01-06-2017 | ORIGINAL ARTICLE

Anti-Inflammatory Effects of Schisandrin B on LPS-Stimulated BV2 Microglia via Activating PPAR-γ

Authors: Na Liu, Jin-Xu Zheng, Yuan-Su Zhuang, Zhi-Kui Zhou, Jin-Hua Zhao, Lei Yang

Published in: Inflammation | Issue 3/2017

Login to get access

Abstract

Schisandrin B (Sch B), a dibenzocyclooctadiene lignan isolated from Schisandra chinensis (Turcz.) Baill, has been shown to have anti-inflammatory effect. The purpose of this study was to evaluate the effect of Sch B on LPS-induced inflammation in microglia and to investigate the molecular targets of Sch B. BV2 cells were stimulated by LPS in the presence or absence of Sch B. The results showed that the levels of TNF-α, IL-6, IL-1β, and PGE2 upregulated by LPS were significantly suppressed by Sch B. LPS-induced NF-κB activation was also inhibited by Sch B. Furthermore, Sch B was found to upregulate the expression of PPAR-γ in a concentration-dependent manner. In addition, the inhibition of Sch B on TNF-α, IL-6, IL-1β, and PGE2 production were reversed by PPAR-γ antagonist GW9662. In conclusion, these results suggested that Sch B inhibited LPS-induced inflammatory response by activating PPAR-γ.
Literature
1.
Nimmerjahn, A., F. Kirchhoff, and F. Helmchen. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308: 1314–1318.CrossRefPubMed
2.
Ransohoff, R.M., and V.H. Perry. 2009. Microglial physiology: unique stimuli, specialized responses. Annual Review of Immunology 27: 119–145.CrossRefPubMed
3.
Kang, S.Y., H.W. Jung, M.Y. Lee, H.W. Lee, S.W. Chae, and Y.K. Park. 2014. Effect of the semen extract of Cuscuta chinensis on inflammatory responses in LPS-stimulated BV-2 microglia. Chinese Journal of Natural Medicines 12: 573–581.CrossRefPubMed
4.
5.
Teeling, J.L., and V.H. Perry. 2009. Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 158: 1062–1073.CrossRefPubMed
6.
Hebert, L.E., L.A. Beckett, P.A. Scherr, and D.A. Evans. 2001. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Disease and Associated Disorders 15: 169–173.CrossRefPubMed
7.
Qian, L., P.M. Flood, and J.S. Hong. 2010. Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. Journal of Neural Transmission 117: 971–979.CrossRefPubMedPubMedCentral
8.
Minghetti, L. 2005. Role of inflammation in neurodegenerative diseases. Current Opinion in Neurology 18: 315–321.CrossRefPubMed
9.
Zeng, K.W., T. Zhang, H. Fu, G.X. Liu, and X.M. Wang. 2012. Schisandrin B exerts anti-neuroinflammatory activity by inhibiting the Toll-like receptor 4-dependent MyD88/IKK/NF-kappa B signaling pathway in lipopolysaccharide-induced microglia. European Journal of Pharmacology 692: 29–37.CrossRefPubMed
10.
Leong, P.K., and K.M. Ko. 2015. Schisandrin B induces an Nrf2-mediated thioredoxin expression and suppresses the activation of inflammasome in vitro and in vivo. BioFactors 41: 314–323.CrossRefPubMed
11.
Cai, Z., J. Liu, H. Bian, J. Cai, and G. Zhu. 2016. Suppression of P2X7/NF-kappaB pathways by Schisandrin B contributes to attenuation of lipopolysaccharide-induced inflammatory responses in acute lung injury. Archives of Pharmacal Research 39: 499–507.CrossRefPubMed
12.
Liu, W., Y. Liu, Z. Wang, T. Yu, Q. Lu, and H. Chen. 2015. Suppression of MAPK and NF-kappa B pathways by schisandrin B contributes to attenuation of DSS-induced mice model of inflammatory bowel disease. Pharmazie 70: 598–603.PubMed
13.
Block, M.L., L. Zecca, and J.S. Hong. 2007. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 8: 57–69.CrossRefPubMed
14.
15.
Long-Smith, C.M., A.M. Sullivan, and Y.M. Nolan. 2009. The influence of microglia on the pathogenesis of Parkinson’s disease. Progress in Neurobiology 89: 277–287.CrossRefPubMed
16.
Tweedie, D., K. Sambamurti, and N.H. Greig. 2007. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: New drug candidates and targets. Current Alzheimer Research 4: 378–385.CrossRefPubMed
17.
Karin, M., and F.R. Greten. 2005. NF kappa B: Linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology 5: 749–759.CrossRefPubMed
18.
Wang, H.Y., H. Wang, J.H. Wang, Q. Wang, Q.F. Ma, and Y.Y. Chen. 2015a. Protocatechuic Acid Inhibits Inflammatory Responses in LPS-Stimulated BV2 Microglia via NF-kappa B and MAPKs Signaling Pathways. Neurochemical Research 40: 1655–1660.CrossRefPubMed
19.
Chow, Y.L., K.H. Lee, S. Vidyadaran, N.H. Lajis, M.N. Akhtar, D.A. Israf, and A. Syahida. 2012. Cardamonin from Alpinia rafflesiana inhibits inflammatory responses in IFN-gamma/LPS-stimulated BV2 microglia via NF-kappa B signalling pathway. International Immunopharmacology 12: 657–665.CrossRefPubMed
20.
Zhu, J.Y., L. Jiang, Y.Q. Liu, W.Y. Qian, J.L. Liu, J. Zhou, R. Gao, H. Xiao, and J. Wang. 2015. MAPK and NF-kappa B Pathways Are Involved in Bisphenol A-Induced TNF-alpha and IL-6 Production in BV2 Microglial Cells. Inflammation 38: 637–648.CrossRefPubMed
21.
Wang, Y.M., J. Zhou, S. Fu, C. Wang, and B. Zhou. 2015b. Preventive Effects of Protocatechuic Acid on LPS-Induced Inflammatory Response in Human Gingival Fibroblasts via Activating PPAR-gamma. Inflammation 38: 1080–1084.CrossRefPubMed
22.
Takagi, T., Y. Naito, N. Tomatsuri, O. Handa, H. Ichikawa, N. Yoshida, and T. Yoshikawa. 2002. Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappa B-cytokine cascade. Redox Report 7: 283–289.CrossRefPubMed
23.
Zhang, Y.F., X.L. Zou, J. Wu, X.Q. Yu, and X. Yang. 2015. Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-gamma Agonist, Attenuates Inflammation Via NF-kappa B Inhibition in Lipopolysaccharide-Induced Peritonitis. Inflammation 38: 2105–2115.CrossRefPubMed
24.
Corsi, L., B.M. Dongmo, and R. Avallone. 2015. Supplementation of omega 3 fatty acids improves oxidative stress in activated BV2 microglial cell line. International Journal of Food Sciences and Nutrition 66: 293–299.CrossRefPubMed
Metadata
Title
Anti-Inflammatory Effects of Schisandrin B on LPS-Stimulated BV2 Microglia via Activating PPAR-γ
Authors
Na Liu
Jin-Xu Zheng
Yuan-Su Zhuang
Zhi-Kui Zhou
Jin-Hua Zhao
Lei Yang
Publication date
01-06-2017
Publisher
Springer US
Published in
Inflammation / Issue 3/2017
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-017-0544-2

Other articles of this Issue 3/2017

Inflammation 3/2017 Go to the issue

ORIGINAL ARTICLE

Progranulin Protects Against Osteonecrosis of the Femoral Head by Activating ERK1/2 Pathway

ORIGINAL ARTICLE

Protective Effect of Amygdalin on LPS-Induced Acute Lung Injury by Inhibiting NF-κB and NLRP3 Signaling Pathways

ORIGINAL ARTICLE

Atorvastatin and Simvastatin Promoted Mouse Lung Repair After Cigarette Smoke-Induced Emphysema

ORIGINAL ARTICLE

Quercetin and Ascorbic Acid Suppress Fructose-Induced NLRP3 Inflammasome Activation by Blocking Intracellular Shuttling of TXNIP in Human Macrophage Cell Lines

ORIGINAL ARTICLE

Prostaglandin E2 Upregulated Trigeminal Ganglionic Sodium Channel 1.7 Involving Temporomandibular Joint Inflammatory Pain in Rats

ORIGINAL ARTICLE

The Influence of α-Tocopherol on Serum Biochemical Markers During Experimentally Induced Pleuritis in Rats Exposed to Dioxin
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits